Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

Thank you for standing by. My name is Pam and I will be your conference Operator today. At this time, I would like to welcome everyone to the DuPont third quarter 2024 earnings conference call. All ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Dollar Tree (DLTR) faces CEO transition and market uncertainty as analysts weigh in on strategic measures and potential ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...